Activist Investor 13D Filings


This table shows recent activist investor (Schedule 13D) filings made in this industry. Any investor or hedge fund that makes an investment with the intention of influencing management is considered an activist investor and must file a 13D.

DateFormInvestorTargetSharesOwnership
(Percent)
Ownership Change
(Percent)
2018‑02‑15 SC 13D GREAT POINT PARTNERS LLC BCRX / BioCryst Pharmaceuticals 7,478,275 7.6
2018‑02‑15 SC 13D/A ORBIMED ADVISORS LLC XTNT / Xtant Medical Holdings 9,214,321 70.4 224.57
2018‑02‑14 SC 13D/A CELGENE CORP /DE/ JUNO / Juno Therapeutics 11,109,160 9.7 0.00
2018‑02‑14 SC 13D/A SOFINNOVA VENTURE PARTNERS VII L P CHRS / Coherus BioSciences 2,987,056 5.0 0.64
2018‑02‑14 SC 13D Sailing Capital Overseas Investments Fund, Lp CBMG / Cellular Biomedicine Group 1,712,920
2018‑02‑13 SC 13D/A Digirad Corp BOTA / Biota Pharmaceuticals 3,195,106 8.3 0.00
2018‑02‑13 SC 13D/A GLAXOSMITHKLINE PLC GNCA / Genocea Biosciences 2,121,668 2.6 0.00
2018‑02‑09 SC 13D/A Clarus Lifesciences I, L.P. VBIV / VBI Vaccines, Inc. 2,691,042 4.22 0.00
2018‑02‑07 SC 13D/A BRATTON DOUGLAS K JUNO / Juno Therapeutics 5,433,301 4.7 -28.77
2018‑02‑05 SC 13D/A Baker Brothers Advisors LP SGEN / Seattle Genetics 49,818,661 31.7 8.37
2018‑02‑02 SC 13D/A CELGENE CORP /DE/ JUNO / Juno Therapeutics 11,109,160 9.7 0.00
2018‑01‑26 SC 13D/A ORBIMED ADVISORS LLC ADAP / Adaptimmune Therapeutics 36,896,260 6.56 31.58
2018‑01‑26 SC 13D New Enterprise Associates 16, L.p. GNCA / Genocea Biosciences 37,500,000 39.7
2018‑01‑22 SC 13D/A CELGENE CORP /DE/ JUNO / Juno Therapeutics 11,109,160 9.7
2018‑01‑18 SC 13D/A SC Fundamental Value Fund, L.P. BOTA / Biota Pharmaceuticals 1,868,143 4.83 -23.12
2018‑01‑17 SC 13D/A ORBIMED ADVISORS LLC XTNT / Xtant Medical Holdings 2,838,903 13.82 45.39
2018‑01‑16 SC 13D/A Digirad Corp BOTA / Biota Pharmaceuticals 3,195,106 8.3 0.00
2018‑01‑12 SC 13D He Wei-wu CASI / CASI Pharmaceuticals 6,219,539 9.1
2018‑01‑10 SC 13D Pw Medtech Group Ltd CBPO / China Biologic Products 5,521,000 16.7
2017‑12‑29 SC 13D Digirad Corp BOTA / Biota Pharmaceuticals 3,195,106 8.3
2017‑12‑19 SC 13D Essetifin Spa FENCF / Fennec Pharmaceuticals 3,225,694 17.7
2017‑12‑04 SC 13D/A Flynn James E PRTO / Proteon Therapeutics 17,306,917 9.985 0.00
2017‑12‑01 SC 13D/A PTV SCIENCES II L P LPTN / Lpath 4,202,140 24.3 -23.11
2017‑11‑21 SC 13D Lee's Pharmaceutical Holdings Ltd DSCO / Discovery Laboratories 48,908,085 74.0
2017‑11‑20 SC 13D/A Biotest AG ADMA / ADMA Biologics 18,700,694 41.27 335.35
2017‑11‑16 SC 13D/A Aisling Capital II LP ADMA / ADMA Biologics 3,608,171 8.0 0.00
2017‑11‑15 SC 13D/A BIOTIME INC AST / Asterias Biotherapeutics 40.16
2017‑11‑15 SC 13D/A BIOTIME INC AST / Asterias Biotherapeutics 13.0
2017‑11‑13 SC 13D/A Flynn James E AVXS / AveXis 1,547,386 4.84 -16.71
2017‑11‑13 SC 13D/A BLECH ISAAC GNMX / Aevi Genomic Medicine 1,692,334 2.9
2017‑11‑09 SC 13D/A SC Fundamental Value Fund, L.P. BOTA / Biota Pharmaceuticals 2,429,864 6.29 23.18
2017‑11‑08 SC 13D/A BRATTON DOUGLAS K JUNO / Juno Therapeutics 7,628,282 6.7 -18.40
2017‑11‑01 SC 13D/A Vivo Ventures VI, LLC CLDN / Celladon 1,787,091 17.5 11.72
2017‑10‑30 SC 13D/A Baker Brothers Advisors LP IDRA / Idera Pharmaceuticals 18,619,136 9.9 77.54
2017‑10‑17 SC 13D Children's Hospital of Philadelphia Foundation MDGN / Medgenics 18,697,233 30.08
2017‑09‑26 SC 13D/A Celgene Switzerland LLC JUNO / Juno Therapeutics 11,109,160 9.7 7.33
2017‑09‑25 SC 13D/A CELGENE CORP /DE/ XLRN / Acceleron Pharma 6,157,458 13.87 13.78
2017‑09‑25 SC 13D/A PTV SCIENCES II L P LPTN / Lpath 5,464,826 31.7 31.60
2017‑09‑18 SC 13D/A Polaris Venture Partners VI, L.P. EDIT / Editas Medicine 1,797,144 4.3 -35.75
2017‑09‑08 SC 13D/A Flynn James E AVXS / AveXis 1,857,862 5.82 -20.06
2017‑09‑06 SC 13D/A SOFINNOVA VENTURE PARTNERS VII L P CHRS / Coherus BioSciences 2,968,115 5.8 0.00
2017‑09‑05 SC 13D/A SOFINNOVA VENTURE PARTNERS VII L P CHRS / Coherus BioSciences 2,968,115 5.8 1.12
2017‑08‑31 SC 13D/A SCOPIA CAPITAL MANAGEMENT LP ACOR / Acorda Therapeutics 8,474,728 18.2 9.94
2017‑08‑22 SC 13D/A Flynn James E AVXS / AveXis 2,324,060 7.28 3.19
2017‑08‑22 SC 13D/A Flynn James E PRTO / Proteon Therapeutics 17,306,917 9.985 0.00
2017‑08‑16 SC 13D/A Novo A/S LPTN / Lpath 671,872 3.9 -37.85
2017‑08‑14 SC 13D/A Novo A/S LPTN / Lpath 1,081,072 6.3 -16.21
2017‑08‑08 SC 13D/A PESSIN NORMAN H CSBR / Champions Oncology 742,161 6.8 29.63
2017‑08‑07 SC 13D SCOPIA CAPITAL MANAGEMENT LP ACOR / Acorda Therapeutics 7,708,527 16.5 38.44
2017‑08‑04 SC 13D/A Flynn James E PRTO / Proteon Therapeutics 17,306,917 9.985 1,312.93